Match!

Hormone therapy for preventing cardiovascular disease in post‐menopausal women

Published on Mar 10, 2015in Cochrane Database of Systematic Reviews7.755
· DOI :10.1002/14651858.CD002229.PUB4
Henry Boardman11
Estimated H-index: 11
(John Radcliffe Hospital),
Louise Hartley33
Estimated H-index: 33
(Warw.: University of Warwick)
+ 5 AuthorsBeatrice Knight16
Estimated H-index: 16
(University of Exeter)
Sources
Abstract
Background Evidence from systematic reviews of observational studies suggests that hormone therapy may have beneficial effects in reducing the incidence of cardiovascular disease events in post-menopausal women, however the results of randomised controlled trials (RCTs) have had mixed results. This is an updated version of a Cochrane review published in 2013. Objectives To assess the effects of hormone therapy for the prevention of cardiovascular disease in post-menopausal women, and whether there are differential effects between use in primary or secondary prevention. Secondary aims were to undertake exploratory analyses to (i) assess the impact of time since menopause that treatment was commenced (≥ 10 years versus < 10 years), and where these data were not available, use age of trial participants at baseline as a proxy (≥ 60 years of age versus < 60 years of age); and (ii) assess the effects of length of time on treatment. Search methods We searched the following databases on 25 February 2014: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE and LILACS. We also searched research and trials registers, and conducted reference checking of relevant studies and related systematic reviews to identify additional studies. Selection criteria RCTs of women comparing orally administered hormone therapy with placebo or a no treatment control, with a minimum of six months follow-up. Data collection and analysis Two authors independently assessed study quality and extracted data. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for each outcome. We combined results using random effects meta-analyses, and undertook further analyses to assess the effects of treatment as primary or secondary prevention, and whether treatment was commenced more than or less than 10 years after menopause. Main results We identified six new trials through this update. Therefore the review includes 19 trials with a total of 40,410 post-menopausal women. On the whole, study quality was good and generally at low risk of bias; the findings are dominated by the three largest trials. We found high quality evidence that hormone therapy in both primary and secondary prevention conferred no protective effects for all-cause mortality, cardiovascular death, non-fatal myocardial infarction, angina, or revascularisation. However, there was an increased risk of stroke in those in the hormone therapy arm for combined primary and secondary prevention (RR 1.24, 95% CI 1.10 to 1.41). Venous thromboembolic events were increased (RR 1.92, 95% CI 1.36 to 2.69), as were pulmonary emboli (RR 1.81, 95% CI 1.32 to 2.48) on hormone therapy relative to placebo. The absolute risk increase for stroke was 6 per 1000 women (number needed to treat for an additional harmful outcome (NNTH) = 165; mean length of follow-up: 4.21 years (range: 2.0 to 7.1)); for venous thromboembolism 8 per 1000 women (NNTH = 118; mean length of follow-up: 5.95 years (range: 1.0 to 7.1)); and for pulmonary embolism 4 per 1000 (NNTH = 242; mean length of follow-up: 3.13 years (range: 1.0 to 7.1)). We performed subgroup analyses according to when treatment was started in relation to the menopause. Those who started hormone therapy less than 10 years after the menopause had lower mortality (RR 0.70, 95% CI 0.52 to 0.95, moderate quality evidence) and coronary heart disease (composite of death from cardiovascular causes and non-fatal myocardial infarction) (RR 0.52, 95% CI 0.29 to 0.96; moderate quality evidence), though they were still at increased risk of venous thromboembolism (RR 1.74, 95% CI 1.11 to 2.73, high quality evidence) compared to placebo or no treatment. There was no strong evidence of effect on risk of stroke in this group. In those who started treatment more than 10 years after the menopause there was high quality evidence that it had little effect on death or coronary heart disease between groups but there was an increased risk of stroke (RR 1.21, 95% CI 1.06 to 1.38, high quality evidence) and venous thromboembolism (RR 1.96, 95% CI 1.37 to 2.80, high quality evidence). Authors' conclusions Our review findings provide strong evidence that treatment with hormone therapy in post-menopausal women overall, for either primary or secondary prevention of cardiovascular disease events has little if any benefit and causes an increase in the risk of stroke and venous thromboembolic events.
  • References (216)
  • Citations (161)
📖 Papers frequently viewed together
200251.27JAMA
12.1k Citations
201351.27JAMA
588 Citations
392 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References216
Newest
#1Julian P T Higgins (UoB: University of Bristol)H-Index: 106
#2Sally Green (UCL: University College London)H-Index: 50
The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
8,637 Citations
1,140 Citations
Objectives: To investigate the relationship between the menopausal status and related hormonal variation of oestradiol with plasma lipid concentrations. Material and Methods: Fifty premenopausal women and fifty postmenopausal women subjects were selected. Data was collected through clinical evaluation from questionnaires and laboratory investigations. Plasma oestradiol and lipid profile determinations were done by using competitive binding immunoassay methods and enzymatic methods respectively. ...
30 CitationsSource
#1Whitney Wharton (UW: University of Wisconsin-Madison)H-Index: 17
#2Carey E. Gleason (UW: University of Wisconsin-Madison)H-Index: 26
Last. Sanjay Asthana (UW: University of Wisconsin-Madison)H-Index: 51
view all 4 authors...
Abstract This manuscript describes the study design and rationalle for the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective ancillary study (KEEPS Cog). KEEPS is a multicenter, randomized, double-blinded, placebo-controlled trial, designed to test the hypothesis that low-dose hormone therapy (HT) initiated in recently postmenopausal women will reduce the progression of subclinical atherosclerosis as measured by carotid artery intima-media thickness (CIMT) and ...
48 CitationsSource
#1Jacques E. RossouwH-Index: 47
#2JoAnn E. MansonH-Index: 240
Last. Garnet L. AndersonH-Index: 70
view all 4 authors...
Prior to 2002, prescriptions for menopausal hormone therapy (HT) were climbing, professional organizations were recommending menopausal HT for prevention of osteoporosis and coronary heart disease (CHD), and one third of prescriptions were for women aged older than 60 years. Against this background, the National Institutes of Health launched the Women’s Health Initiative (WHI) randomized trials of menopausal HT to test whether the association with reduced risk for CHD found in observational stud...
58 CitationsSource
#1T TownsendH-Index: 1
Last. Mike Rayner (University of Oxford)H-Index: 55
view all 8 authors...
56 Citations
#1Louise Lind Schierbeck (Hvidovre Hospital)H-Index: 6
#2Lars RejnmarkH-Index: 60
Last. Jens-Erik Beck Jensen (Hvidovre Hospital)H-Index: 26
view all 8 authors...
392 CitationsSource
#1Susan Furness (University of Manchester)H-Index: 20
#2Helen Roberts (University of Auckland)H-Index: 16
Last. Anne Lethaby (University of Auckland)H-Index: 35
view all 4 authors...
Background Reduced circulating estrogen levels around the time of the menopause can induce unacceptable symptoms that affect the health and well-being of women. Hormone therapy (both unopposed estrogen and estrogen/progestogen combinations) is an effective treatment for these symptoms, but is associated with risk of harms. Guidelines recommend that hormone therapy be given at the lowest effective dose and treatment should be reviewed regularly. The aim of this review is to identify the minimum d...
108 CitationsSource
#1Vinod Yalamanchili (Creighton University)H-Index: 5
Objective To examine the effect of hormone therapy and calcitriol on depression in elderly postmenopausal women and also to determine whether the response was associated with polymorphisms of estrogen receptor-alpha and vitamin D receptor.
31 CitationsSource
#1Sebastian MirkinH-Index: 20
#2Jennifer A. HarveyH-Index: 25
Last. Arkadi A. ChinesH-Index: 36
view all 6 authors...
3 CitationsSource
Cited By161
Newest
#1Tao Jiang (SJTU: Shanghai Jiao Tong University)H-Index: 1
#2Wei Yan (SJTU: Shanghai Jiao Tong University)H-Index: 1
Last. Min Jiang (SJTU: Shanghai Jiao Tong University)H-Index: 8
view all 12 authors...
Abstract Osteoclasts are the only cells in the body with a bone-resorption function. The identification of anti-osteoclastogenic agents is important in managing bone loss diseases. The dried vines of Trachelospermum jasminoides (Lindl.) Lem. have been used as a herbal medicine to treat musculoskeletal soreness in East Asia for hundreds of years. In the present study, we focused on the effect of Trachelospermum jasminoides (Lindl.) Lem. extract (TJE) on osteoclast differentiation. As indicated by...
Source
#1Jennifer L. Gordon (University of Regina)H-Index: 8
#2David R. Rubinow (UNC: University of North Carolina at Chapel Hill)H-Index: 29
Last. Susan S. Girdler (UNC: University of North Carolina at Chapel Hill)H-Index: 39
view all 6 authors...
BACKGROUND: The arterial effects of hormone therapy remain controversial. This study tested the effects of transdermal estradiol plus intermittent micronized progesterone (TE + IMP) in healthy perimenopausal and early postmenopausal women on several mechanisms involved in the pathophysiology of arterial disease. METHODS: Healthy perimenopausal and early postmenopausal women, ages 45 to 60 years, were enrolled in this randomized, double-blind, placebo-controlled trial. Women were randomized to re...
Source
Peri life. Hormone replacement therapy (HRT) might be necessary in order to decrease women's symptoms. The German S3 guideline "Peri- and Postmenopause-Diagnostics and Therapy" (2020) provides recommendations that include the most recent evidence as well as the Women's Health Initiative (WHI) study results from 2002 and 2004. These results led to reduced prescription patterns due to a high risk of cardiovascular diseases as well as an increased risk for breast cancer if HRT had been administered...
Source
#1Nora Johansen (University of Oslo)H-Index: 2
#2Serena Tonstad (Oslo University Hospital)H-Index: 35
Last. Trond M. Michelsen (Oslo University Hospital)H-Index: 10
view all 6 authors...
INTRODUCTION: Breast cancer susceptibility gene (BRCA) mutation carriers are recommended to undergo early oophorectomy to prevent ovarian cancer. Premature loss of ovarian hormones may increase the risk of cardiovascular disease. Because women with preventive oophorectomy are mainly young and healthy, they rarely undergo specialized cardiological surveillance. We compared the risk of cardiovascular disease in women after preventive oophorectomy with reference women. METHODS: In an historical coh...
Source
#1Vivien Herman-Bonert (Cedars-Sinai Medical Center)H-Index: 21
Hyperprolactinemia is associated with suppression of the hypothalamic- pituitary-gonadal axis and consequent hypogonadism, manifesting loss of libido, infertility and osteoporosis long-term in both male and female patients, with associated menstrual irregularities, amenorrhea and galactorrhea in women and erectile dysfunction in men. The primary goals of therapy in patients harboring prolactinoma are control of tumor size and normalization of serum PRL, with restoration of gonadal and sexual fun...
Source
#1Ahmed Haider (UZH: University of Zurich)H-Index: 6
#2Susan Bengs (UZH: University of Zurich)H-Index: 6
Last. Catherine Gebhard (Medical University of Vienna)H-Index: 19
view all 7 authors...
Although health disparities in women presenting with acute coronary syndrome (ACS) have received growing attention in recent years, clinical outcomes from ACS are still worse for women than for men. Women continue to experience higher patient and system delays and receive less aggressive invasive treatment and pharmacotherapies. Gender- and sex-specific variables that contribute to ACS vulnerability remain largely unknown. Notwithstanding the sex differences in baseline coronary anatomy and func...
7 CitationsSource
#1Byung-Koo Yoon (SMC: Samsung Medical Center)H-Index: 20
#1Byung Koo Yoon (SMC: Samsung Medical Center)H-Index: 5
Last. Chi-Dug Kang (PNU: Pusan National University)H-Index: 25
view all 7 authors...
OBJECTIVES: When administered soon after menopause, hormone therapy can prevent coronary heart diseases in women. To explore the mechanism underlying the cardioprotective actions of estrogen, we investigated the effects of 17beta-estradiol (17beta-E(2)) on the plasminogen activator system using cultured vascular smooth muscle cells (VSMCs). METHODS: VSMCs were isolated from rat aortas. Protein expression of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-P...
Source
#1Emma O’Lone (USYD: University of Sydney)H-Index: 12
#2Patrick J. Kelly (USYD: University of Sydney)H-Index: 25
Last. Angela C. Webster (USYD: University of Sydney)H-Index: 53
view all 8 authors...
Background The incidence of ischaemic heart disease (IHD) has fallen consistently in the general population; attributed to effective primary prevention strategies. Differences in incidence have been demonstrated by sex. Whether this fall in incidence and sex differences is mirrored in people with end-stage kidney disease (ESKD) is unclear. We aimed to establish the relative risk of IHD events in the ESKD population. Methods We performed a retrospective cohort study from 2000 to 2010 in people wi...
Source
#1Anne Gompel (Paris V: Paris Descartes University)H-Index: 41
La Presse medicale Formation - Sous presse. Epreuves corrigees par l'auteur. Disponible en ligne depuis le jeudi 19 mars 2020
Source
Source